Cite
MLA Citation
J Jones et al.. “P037 Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor.” Journal of Crohn's and colitis, vol. 15, n.d., pp. S149–S150. http://access.bl.uk/ark:/81055/vdc_100130765682.0x000007